
Sinotau Pharmaceutical Group Completes $50 Million D+ Round of Financing with Focus on Radiopharmaceutical R&D
Sinotau Pharmaceutical Group announced in a document on Thursday that it has completed a D+ round of financing worth 320 million yuan ($50.03 million). The funds raised are for clinical R&D of new radioactive drugs.